China Microarray Market Size, Share, Trends & Forecast Analysis by Product (Consumables [Kits: DNA & RNA, Protein, Tissue, Other Microarray Kits; Other Consumables], Instruments, Software, Services), Application, and End User - Forecast to 2036

The China Microarray Market was valued at USD 569.0 million in 2025. It is estimated to reach USD 622.5 million in 2026 and is projected to grow to USD 1.62 billion by 2036, at a CAGR of 10.0% during the forecast period. This report offers a detailed look at the market, covering key trends, regulations, pricing, competitive activity, and future growth opportunities.

Microarray technology detects and measures large numbers of nucleic acids or proteins in samples such as cells, tissues, or body fluids. It relies on consumables such as microarray kits, which are read using microarray scanners and analyzed with dedicated software. Microarray kits are used to study protein families, analyze serum for diagnostic purposes, profile how genes respond to drugs, and examine cells exposed to specific stimuli. The China microarray market covers the sale of microarray consumables, instruments, software, and services to organizations operating in China.

According to the National Bureau of Statistics of China, national spending on research and development reached RMB 3.93 trillion in 2025, up 8.1% from the previous year, with R&D intensity at 2.80% of GDP, above the OECD average for the first time. China also recorded 4,824,703 new cancer cases and 2,574,176 cancer deaths in 2022, according to IARC GLOBOCAN estimates. On the policy side, Illumina was placed on China's Unreliable Entity List in February 2025, followed by an import ban on its genetic sequencers that lasted until November 2025, and national policies favoring domestically made laboratory equipment have encouraged buyers to consider Chinese suppliers.

The report examines market dynamics, macro indicators, key trends, regulations, pricing, PESTLE factors, the wider IVD industry, and competitive strategies. It also provides market forecasts and segment-level insights to support business, investment, and product decisions in China.

Market Dynamics

Microarrays are used in a growing range of research areas in China, including genomics, proteomics, pharmacogenomics, and personalized medicine. Rising cancer and genetic disorder rates are increasing demand for tools that can analyze many genes or proteins at once, and pharmaceutical and biotechnology companies are investing more in research and development. Microarrays are also moving into new areas such as forensics, and the use of 3D-printed microarrays is growing.

Microarrays cost more than some other genetic testing methods, and next-generation sequencing is increasingly used for applications where microarrays were once the standard choice. China's centralized volume-based procurement of in vitro diagnostic reagents is also pushing prices down in public hospitals, although products used mainly for research are less affected. In addition, concerns about sensitivity and accuracy with some samples remain a challenge for wider use.

New advances in microarray technology and the growing use of personalized medicine are expected to open up new opportunities in China. Microarray-based genotyping is also expanding into crop and livestock breeding, creating demand beyond human health. National policies that favor locally made laboratory equipment offer further opportunities for domestic suppliers, especially as Chinese companies begin to offer complete microarray platforms.

Segment Analysis

The report analyzes the market by product, application, and end user, helping stakeholders identify the most promising growth opportunities in China.

Based on product, the market is segmented into consumables (kits, including DNA & RNA microarray kits, protein microarray kits, tissue microarray kits, and other microarray kits, as well as other consumables), instruments, software, and services. In 2026, consumables are expected to account for the largest share of 63.6% of the market and also record the fastest growth. Kits and reagents are bought for each sample rather than once per instrument, so demand rises directly with testing volume. Rising cancer rates, the wide range of microarray applications, and growing funding for genomic research further support this segment.

Based on application, the market is segmented into drug discovery & development, research applications, diagnostics, and other applications. In 2026, drug discovery & development is expected to hold the largest share of 51.8%, supported by rising public and private investment in pharmaceutical and biotechnology research and efforts by companies to expand their research capabilities. Research applications are expected to grow the fastest, driven by the high sensitivity of microarray technologies, their low sample requirements, and their cost-effectiveness.

Based on end user, the market is segmented into pharmaceutical and biotechnology companies, contract research organizations (CROs), academic & research institutes, hospitals & diagnostic laboratories, and other end users. In 2026, pharmaceutical and biotechnology companies are expected to hold the largest share of 35.7%, due to high R&D spending, growing demand for new drugs, and increasing funding for genomic research. Contract research organizations are expected to grow the fastest, as more drug discovery and development work is outsourced to specialist providers.

Competitive Landscape

The report provides a detailed review of the competitive landscape, covering growth strategies, benchmarking by product, market positioning, market shares, product portfolios, strategic developments, and financial performance of leading companies.

The China microarray market is consolidated. In 2025, Thermo Fisher Scientific, Inc., Illumina, Inc., Merck KGaA, Agilent Technologies, Inc., and Revvity, Inc. together accounted for a major share of the market. International suppliers lost some share to domestic companies during 2025, due to the regulatory action against Illumina, policy support for locally made equipment, and price pressure from centralized procurement. International suppliers remain strongest in research-use products, where product range and proven workflows matter most, while domestic suppliers are gaining ground in publicly procured clinical testing and agricultural genotyping. Suzhou LASO Biotech, founded in 2018, began selling a complete domestically developed microarray platform in 2024, including scanners, customizable arrays, reagents, and software.

Leading companies are pursuing product launches, partnerships, collaborations, acquisitions, and expansions. Thermo Fisher Scientific completed its USD 3.1 billion acquisition of Olink in 2024, adding proteomics capabilities to its Axiom array range. Illumina completed its acquisition of SomaLogic in January 2026, and Merck KGaA agreed in 2026 to acquire Bio-Techne Corporation to strengthen its life science business in multiomics and precision diagnostics.

Key companies profiled in the report include Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), Merck KGaA (Germany), Agilent Technologies, Inc. (U.S.), Revvity, Inc. (U.S.), QIAGEN N.V. (Netherlands), Sino Biological, Inc. (China), CapitalBio Technology Co., Ltd. (China), Arrayit Corporation (U.S.), RayBiotech Life, Inc. (U.S.), and Suzhou LASO Biotech Co., Ltd. (China).

How This Report Helps

• Provides reliable market size estimates and long-term forecasts for the China microarray market.
• Explains how R&D investment, cancer burden, sequencing competition, procurement reform, and domestic substitution policies affect market growth.
• Identifies high-growth opportunities across product, application, and end user segments.
• Analyzes key trends, regulations, pricing, PESTLE factors, and company strategies shaping the market in China.
• Benchmarks leading companies based on their product portfolios, strategies, and market positions.
• Supports product development, investment planning, partnership evaluation, market entry, and business expansion decisions in China.
• Delivers practical market insights for microarray manufacturers, reagent and consumable suppliers, distributors, research institutions, CROs, diagnostic laboratories, and investors.

Key Questions Answered

• How big is the China microarray market today, and how will it grow through 2036?
• What research, clinical, regulatory, and economic factors are driving market growth?
• What are the main drivers, restraints, opportunities, and challenges shaping the industry in China?
• Which product, application, and end user segments will grow the fastest?
• How are volume-based procurement, next-generation sequencing, and domestic substitution policies affecting microarray demand?
• How did the regulatory action against Illumina change the competitive landscape in 2025?
• Who are the leading companies in the market, and what strategies are they following?
• What recent acquisitions, product launches, and partnerships are shaping the competitive landscape?
• How can stakeholders use this report to support investment decisions, product development, competitive benchmarking, and long-term strategy?